Review Article | Published:

New functions for the matrix metalloproteinases in cancer progression

Nature Reviews Cancer volume 2, pages 161174 (2002) | Download Citation

Subjects

Abstract

Matrix metalloproteinases (MMPs) have long been associated with cancer-cell invasion and metastasis. This provided the rationale for clinical trials of MMP inhibitors, unfortunately with disappointing results. We now know, however, that the MMPs have functions other than promotion of invasion, have substrates other than components of the extracellular matrix, and that they function before invasion in the development of cancer. With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic?

Key points

  • The matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that consist of more than 21 human MMPs and numerous homologues from other species. They can be divided into eight structural classes, three of which are membrane bound.

  • The MMPs are synthesized as inactive zymogens and activated by proteinase cleavage. Their activity is regulated by endogenous inhibitors, including α2-macroglobulin; tissue inhibitors of metalloproteinases (TIMPs); small molecules with TIMP-like domains; and the membrane-bound inhibitor RECK (reversion-inducing cysteine-rich protein with kazal motifs).

  • Direct evidence for a role of MMPs in tumour progression comes from xenograft experiments using cancer cells with decreased and increased expression levels of MMPs or TIMPs, and from carcinogenesis experiments with mice that either lack a specific Mmp or Timp-1 or have organ-specific Mmp or Timp-1 overexpression.

  • MMPs are upregulated in almost every type of human cancer, and their expression is often associated with poor survival. Whereas some of the MMPs (for example, MMP-7) are expressed by the cancer cells, other MMPs (for example, MMP-2 and MMP-9) are synthesized by the tumour stromal cells, including fibroblasts, myofibroblasts, inflammatory cells and endothelial cells.

  • MMPs can promote cancer progression by increasing cancer-cell growth, migration, invasion, metastasis and angiogenesis. MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth-factor-binding proteins, growth-factor precursors, receptor tyrosine kinases, cell-adhesion molecules and other proteinases.

  • Several synthetic MMP inhibitors are undergoing Phase III clinical trials. Although a few encouraging results have been reported, some trials were prematurely terminated due to either lack of benefits or major adverse effects.

  • The clinical trials have so far focused on patients with advanced-stage disease. Based on animal experiments, we would expect, however, that clinical efficacy might be improved either by using MMP inhibitors in the treatment of early disease (in combination with conventional therapy), or as preoperative and postoperative treatment to prevent surgical-induced micrometastatic spread and recurrence of the disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & The hallmarks of cancer. Cell 100, 57–70 (2000).

  2. 2.

    & Putting tumours in context. Nature Rev. Cancer 1, 46–54 (2001).

  3. 3.

    ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439–442 (1997).

  4. 4.

    et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85, 683–693 (1996).Localization of active MMP-2, secreted by stromal cells, to the cell surface of invasive cells by binding to αvβ3 integrin is necessary for invasive behaviour. Similar results relating to the importance of invasion, angiogenesis and TGF-β processing of tethering MMP-9 to the cell surface by binding to CD44 were reported in references 5 and 28.

  5. 5.

    & Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13, 35–48 (1999).

  6. 6.

    , , & CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16, 307–323 (2002).

  7. 7.

    & How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463–516 (2001).

  8. 8.

    et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331–5338 (1995).

  9. 9.

    et al. MT1-MMP initiates activation of pro-MMP-2 and integrin αvβ3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 263, 209–223 (2001).

  10. 10.

    et al. Cellular activation of MMP-2 (Gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J. Biol. Chem. 276, 47402–47410 (2001).

  11. 11.

    & Human fibroblast collagenase-α-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian α-macroglobulins. J. Biol. Chem. 264, 393–401 (1989).

  12. 12.

    , & Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276, 8403–8408 (2001).

  13. 13.

    & Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. 275, 32167–32173 (2000).

  14. 14.

    et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 98, 12485–12490 (2001).

  15. 15.

    et al. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 14, 1674–1676 (2000).

  16. 16.

    in Matrix Metalloproteinase Inhibitors in Cancer Therapy (eds Clendeninn, N. J. & Appelt, K.) 67–84 (Humana Press, Totowa, New Jersey, 2001).

  17. 17.

    , & TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 275, 26411–26415 (2000).

  18. 18.

    et al. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J. Biol. Chem. 275, 1384–1390 (2000).

  19. 19.

    , , , & Comparative analysis of the noncollagenous NC1 domain of type IV collagen: identification of structural features important for assembly, function, and pathogenesis. Protein Sci. 7, 1340–1351 (1998).

  20. 20.

    et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789–800 (2001).Reports that deficiency of an MMP inhibitor, RECK, is embryonic lethal, due to a defect in vascular development. Also shows that the blood vessels in tumours that overexpress RECK have a reduced branching phenotype.

  21. 21.

    Extracellular matrix remodelling and cellular differentiation. Curr. Opin. Cell. Biol. 11, 634–640 (1999).

  22. 22.

    , , , & Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 225–228 (1997).Shows, together with reference 100, that cleavage of laminin-5 by MMPs triggers the migration of cells by unmasking a cryptic site that might act as a ligand for an unidentified cellular receptor.

  23. 23.

    et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154, 1069–1080 (2001).Shows that a cryptic site within collagen type IV that is exposed following proteinase cleavage promotes angiogenesis and tumour growth, probably by interacting with αvβ3 integrin. This cryptic site is detected in blood vessels from tumours but not normal tissue.

  24. 24.

    et al. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem. 272, 25706–25712 (1997).

  25. 25.

    et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 274, 6935–6945 (1999).

  26. 26.

    , , & The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271, 10079–10086 (1996).

  27. 27.

    et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281–1284 (1998).

  28. 28.

    & Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163–176 (2000).

  29. 29.

    et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl Acad. Sci. USA 93, 7069–7074 (1996).

  30. 30.

    , , , & Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59, 1196–1201 (1999).

  31. 31.

    , , , & Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J. Biol. Chem. 273, 20589–20595 (1998).

  32. 32.

    , , & Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sci. 114, 1213–1220 (2001).

  33. 33.

    et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 114, 111–118 (2001).

  34. 34.

    et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893–904 (2001).Reports that CD44 is shed by MMP-14 and that mutation of the cleavage site inhibits migration.

  35. 35.

    , , , & Processing of integrin αV subunit by MT1–MMP stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of FAK. J. Biol. Chem. 2001 Nov 27; [epub ahead of print].

  36. 36.

    & Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895–904 (1996).

  37. 37.

    et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140, 1535–1541 (1998).

  38. 38.

    et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048–1051 (1998).

  39. 39.

    et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 17, 177–181 (1999).

  40. 40.

    et al. The stromal proteinase MMP-3/ stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137–146 (1999).Shows, together with reference 95, that active MMP-3 changes the phenotype of mammary epithelial cells to mesenchymal-like cells, and that the E-cadherin–β-catenin complex is involved in this regulation. Expression of an MMP, even when expressed only in the early stages of cancer development, is also sufficient to initiate tumour formation.

  41. 41.

    et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res 61, 984–990 (2001).

  42. 42.

    , , & MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000).In a transgenic mouse model of skin cancer, the reduced carcinogenesis in mice that are deficient for MMP9 can be completely restored by bone-marrow transplantation of MMP9-expressing cells. Tumours that arise in the absence of MMP9 are of a more advanced stage than those that arise in wild-type mice.

  43. 43.

    et al. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 91, 1277–1283 (2001).

  44. 44.

    et al. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn. J. Cancer Res. 88, 72–81 (1997).

  45. 45.

    et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res. 61, 2365–2370 (2001).

  46. 46.

    , , & Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107, 2373–2379 (1994).

  47. 47.

    et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int. J. Cancer 75, 81–87 (1998).

  48. 48.

    et al. Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome Res. 8, 929–939 (1998).

  49. 49.

    et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 59, 2570–2576 (1999).

  50. 50.

    et al. The PEA3 subfamily of Ets transcription factors synergizes with β- catenin–LEF-1 to activate matrilysin transcription in intestinal tumors. Mol. Cell Biol. 21, 1370–1383 (2001).

  51. 51.

    et al. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J. Biol. Chem. 274, 11535–11540 (1999).

  52. 52.

    et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J. Biol. Chem. 275, 11327–11332 (2000).

  53. 53.

    et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 424, 641–645 (1994).

  54. 54.

    et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 59, 4225–4227 (1999).

  55. 55.

    et al. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 61, 1296–1298 (2001).

  56. 56.

    , , , & A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 61, 7825–7829 (2001).

  57. 57.

    et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 271, 13055–13060 (1996).

  58. 58.

    et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin. Chem. 46, 2023–2024 (2000).

  59. 59.

    et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).MMP-9 controls tumour angiogenesis by increasing the bioavailability of VEGF, and is expressed by stromal cells but not by cancer cells. MMP-2 also influences tumour growth but not angiogenesis. Invasion is not affected by MMP-2 or MMP-9.

  60. 60.

    , , , & The αvβ6 integrin promotes proliferation of colon carcinoma cells through a unique region of the β6 cytoplasmic domain. J. Cell Biol. 127, 547–556 (1994).

  61. 61.

    , & TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117–129 (2001).

  62. 62.

    Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11, 68–75 (1999).

  63. 63.

    , , & Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. 135, 1669–1677 (1996).

  64. 64.

    , , & Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res. 55, 1401–1406 (1995).

  65. 65.

    et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J. Cell Biol. 125, 681–693 (1994).

  66. 66.

    , , , & The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9, 1441–1447 (1999).

  67. 67.

    , , , & Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61, 577–581 (2001).

  68. 68.

    et al. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J. Cell Biochem. 82, 549–555 (2001).

  69. 69.

    et al. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 61, 2189–2193 (2001).

  70. 70.

    The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19, 5574–5581 (2000).

  71. 71.

    et al. Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in Xenopus laevis. J. Cell Biol. 150, 1177–1188 (2000).

  72. 72.

    et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411–422 (1998).

  73. 73.

    , , & Cleavage of β-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol. Biol. Cell 9, 1589–1601 (1998).

  74. 74.

    , , & PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J. 15, 362–372 (2001).

  75. 75.

    et al. Cleavage and shedding of E-cadherin after induction of apoptosis. J. Biol. Chem. 276, 4972–4980 (2001).

  76. 76.

    & Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).

  77. 77.

    et al. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab. Invest. 79, 225–234 (1999).

  78. 78.

    et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum. Gene Ther. 12, 515–526 (2001).

  79. 79.

    et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin. Cancer Res. 5, 3603–3607 (1999).

  80. 80.

    , , , & Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 97, 2323–2332 (2001).

  81. 81.

    , , , & The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol. Lett. 57, 83–88 (1997).

  82. 82.

    et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl Acad. Sci. USA 97, 3884–3889 (2000).

  83. 83.

    , , , & Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276, 37491–37500 (2001).

  84. 84.

    , , , & Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365–377 (1998).

  85. 85.

    et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052–4057 (2000).

  86. 86.

    , , & Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801–810 (1997).The first paper to show that MMP cleavage can produce anti-angiogenic fragments of ECM components.

  87. 87.

    et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161, 6845–6852 (1998).

  88. 88.

    et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin. Cancer Res. 6, 1647–1654 (2000).

  89. 89.

    , , , & Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 486, 247–251 (2000).

  90. 90.

    et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315–328 (1994).

  91. 91.

    et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).

  92. 92.

    et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60, 5410–5413 (2000).

  93. 93.

    et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 97, 3123–3131 (2001).

  94. 94.

    , & Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 58, 2310–2315 (1998).

  95. 95.

    et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861–1872 (1997).

  96. 96.

    , & Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J. Cell Biol. 144, 373–384 (1999).

  97. 97.

    , , , & Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res. 17, 3201–3210 (1997).

  98. 98.

    , , & Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int. J. Cancer 97, 283–289 (2002).

  99. 99.

    & Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56, 5279–5284 (1996).

  100. 100.

    , , , & Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148, 615–624 (2000).

  101. 101.

    , & Epithelial–mesenchymal transitions in cancer progression. Acta Anat. (Basel.) 156, 217–226 (1996).

  102. 102.

    et al. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc. Natl Acad. Sci. USA 94, 7959–7964 (1997).

  103. 103.

    et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell Physiol. 176, 206–215 (1998).

  104. 104.

    , , & Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94, 353–362 (1998).

  105. 105.

    et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res. 56, 5678–5683 (1996).

  106. 106.

    et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54, 4791–4797 (1994).

  107. 107.

    , & Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90, 1993–2000 (1997).

  108. 108.

    et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16, 2419–2423 (1998).

  109. 109.

    , , & Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. Oncogene 13, 2307–2314 (1996).

  110. 110.

    & Inflammatory cells and cancer: think different! J. Exp. Med. 193, F23–F26 (2001).

  111. 111.

    et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61, 237–242 (2001).Shows that MMPs can suppress the proliferation of activated T lymphocytes by shedding the interleukin-2 receptor-α from their surface.

  112. 112.

    & Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118–1122 (2001).

  113. 113.

    et al. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am. J. Pathol. 154, 457–468 (1999).

  114. 114.

    , & Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22, 571–579 (2001).

  115. 115.

    et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (2000).MMPs regulate the inflammatory response by cleaving CCL7 — a chemokine that is involved in leukocyte recruitment — thereby converting it to an antagonist of its receptors.

  116. 116.

    et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503–43508 (2001).

  117. 117.

    et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001).

  118. 118.

    et al. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J. Exp. Clin. Cancer Res. 20, 205–212 (2001).

  119. 119.

    et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 60, 6851–6855 (2000).

  120. 120.

    & Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753–767 (2000).

  121. 121.

    et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin. Cancer Res. 5, 1982–1988 (1999).

  122. 122.

    , , , & Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl Acad. Sci. USA 98, 119–124 (2001).Characterizes a compound that inhibits tumour growth by specifically disrupting the protein–protein interaction between MMP-2 and αvβ3 integrin, without any effects on MMP-2 activity in general.

  123. 123.

    , , & Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 60, 6061–6067 (2000).

  124. 124.

    et al. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene 20, 4337–4343 (2001).

  125. 125.

    et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. 60, 5723–5730 (2000).

  126. 126.

    et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol. 17, 768–774 (1999).Characterizes a peptide inhibitor that specifically inhibits the gelatin-binding MMPs, but not other MMPs.

  127. 127.

    , , , & Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447–3455 (2001).

  128. 128.

    et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 11, 1579–1584 (2000).

  129. 129.

    et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12–9566 (9566) in patients (PTS) with advanced pancreatic cancer. ASCO Online [online] (cited 05 Feb 2002), 〈〉 (2000).

  130. 130.

    & Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst. 93, 178–193 (2001).

  131. 131.

    et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949–2954 (2000).

  132. 132.

    et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 21, 145–155 (2001).

  133. 133.

    , , , & Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 28, 620–625 (2001).

  134. 134.

    et al. Tumor invasion: molecular shears blunted by green tea. Nature Med. 5, 1216 (1999).

  135. 135.

    , & Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593–1596 (1991).

  136. 136.

    , & Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 282, 671–677 (2001).

  137. 137.

    , , , & Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812 (1999).

  138. 138.

    et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56, 2815–2822 (1996).

  139. 139.

    & Shedding light on sheddases: role in growth and development. Bioessays 24, 8–12 (2002).

  140. 140.

    ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33, 33–44 (2001).

  141. 141.

    & in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 380–408 (Oxford Univ. Press, Oxford, UK, 1999).

  142. 142.

    et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140–143 (2002).

  143. 143.

    & in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 434–443 (Oxford Univ. Press, Oxford, UK, 1999).

  144. 144.

    in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 422–425 (Oxford Univ. Press, Oxford, UK, 1999).

  145. 145.

    & Insights into extracellular matrix functions from mutant mouse models. Exp. Cell Res. 261, 52–68 (2000).

  146. 146.

    in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 351–356 (Oxford Univ. Press, Oxford, UK, 1999).

  147. 147.

    , , , & Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem. Biophys. Res. Commun. 228, 494–498 (1996).

  148. 148.

    et al. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J. 356, 705–718 (2001).

  149. 149.

    , & Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 275, 33988–33997 (2000).

  150. 150.

    et al. Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase-23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. Mol. Endocrinol. 15, 747–764 (2001).

  151. 151.

    et al. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol. Cell Biol. 15, 5732–5739 (1995).

  152. 152.

    , , & Collagenase induction promotes mouse tumorigenesis by two independent pathways. Mol. Carcinog. 29, 8–16 (2000).

  153. 153.

    Cancer biology: extracellular proteinases in malignancy. Curr. Biol. 9, R776–R778 (1999).

  154. 154.

    , , & The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. 58, 5500–5506 (1998).

  155. 155.

    , , , & Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA 94, 1402–1407 (1997).

  156. 156.

    , , , & Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 13, 569–576 (1996).

  157. 157.

    , , , & The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Ann. NY Acad. Sci. 878, 732–735 (1999).

  158. 158.

    , & Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int. J. Cancer 78, 629–635 (1998).

  159. 159.

    , & Status of matrix metalloproteinase inhibitors as anti-cancer therapeutics. Science (in the press).

Download references

Acknowledgements

We thank B. Wiseman and M. Sternlicht for their helpful comments on the manuscript and apologize for omission of many significant references due to space constraints. This work was supported by grants from the National Cancer Institute and from the Danish Cancer Society.

Author information

Affiliations

  1. Department of Anatomy, University of California at San Francisco, Box 0452, 513 Parnassus, San Francisco, California 94143-0452, USA. egeblad@itsa.ucsf.edu; zena@itsa.ucsf.edu

    • Mikala Egeblad
    •  & Zena Werb

Authors

  1. Search for Mikala Egeblad in:

  2. Search for Zena Werb in:

Supplementary information

Glossary

EXTRACELLULAR MATRIX

All secreted molecules that are immobilized outside cells, see Box 1.

CLINICAL TRIALS

Phase I: the first testing of a new drug in humans. A small group of people is tested to determine drug safety, safe dosage range and side effects. Phase II: the drug is tested on a larger group of patients to see if it is effective and to further evaluate its safety. Phase III: conducted on a large group of patients to confirm the effectiveness, monitor side effects and compare the drug to commonly used treatments.

ZYMOGEN

An enzyme that is secreted by cells as an inactive precursor. Activation of the enzymes occurs as one or more peptide bonds in the zymogen are cleaved.

INTRACELLULAR FURIN-LIKE SERINE PROTEINASES

A family of intracellular proteinases, including furin, that are localized in the trans-Golgi network, where they have an important role in the intracellular processing of secreted proteins.

SCAVENGER RECEPTORS

A broad class of receptors that 'scavenge' cellular debris: the ligands are endocytosed and subsequently degraded. Scavenger receptors also have other activities, such as adhesion.

CRYPTIC SITE

Part of a protein that is normally hidden within the three-dimensional structure. The cryptic site might be exposed following conformational changes in the protein — for example, as a result of proteolytic cleavage.

ADAM

(A disintegrin and metalloproteinase). A family of transmembrane proteinases with metalloproteinase, disintegrin (integrin-binding), cysteine-rich and epidermal growth factor (EGF)-like domains. ADAMs participate in cell-surface proteolysis and cleave substrates such as tumour necrosis factor-α and Notch.

XENOGRAFT

Transplantation of tissue or cells from one species to another. In cancer research, most xenografts are human cancer-cell lines or human tumours that have been transplanted to immune-deficient rodents.

K14-HPV16 MOUSE MODEL OF SQUAMOUS-CELL CARCINOMA

A transgenic mouse strain that expresses the human papillomavirus type 16 (HPV16) early-region genes, including the E6/E7 oncogenes, under the control of the human keratin-14 promoter (K14) in basal keratinocytes. Invasive squamous carcinomas of the epidermis develop through characteristic stages.

RIP-TAg MOUSE MODEL OF ISLET-CELL CARCINOMA

A transgenic mouse strain that expresses the simian virus T antigen (TAg) under the rat insulin II promoter (RIP) in the pancreatic islet β-cells. Carcinomas develop in the pancreatic islets cells and progress through characteristic stages.

PLASMINOGEN

The precursor of plasmin, a trypsin-like serine proteinase that cleaves fibrin in blood clots.

ANGIOSTATIN

A proteolytic fragment of plasminogen and an inhibitor of angiogenesis.

ENDOSTATIN

A proteolytic fragment of the non-collagenous domain of collagen type XVIII and an inhibitor of angiogenesis.

UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR

(uPAR). A cell-surface receptor for urokinase-type plasminogen activator (uPA), a serine proteinase that catalyses the formation of plasmin from plasminogen.

METASTASIS ASSAYS

In spontaneous metastasis assays, the tumour cells are inoculated either subcutaneously or orthotopically in animals, and spontaneous metastases from this primary site to distant locations are monitored. In experimental metastasis assays, tumour cells are injected into the bloodstream (for example, intravenously for lung metastasis, into the left heart ventricle for bone metastases and into the portal vein for liver metastases), thereby circumventing the first steps in the metastatic process.

MATRIGEL

The extracellular matrix secreted by the Engelbrecht–Holm–Swarm mouse sarcoma cell line. It contains laminin, collagen IV, nidogen/entactin and proteoglycans, and so resembles the basement membrane.

HYALURONAN

A high molecular weight glycosaminoglycan. It is widely distributed both in the extracellular matrix and at the cell surface.

INVADOPODIA

Specialized membrane protrusions (also known as an invasive pseudopodia) where active extracellular matrix degradation takes place.

INTRAVASATION

Passage from tissue into blood or lymph vessel.

EXTRAVASATION

Passage from blood or lymph vessel into tissue.

CHEMOKINES

A family of chemotactic proteins that are divided into C, CC, CXC and CX3C chemokines, depending on the number and spacing of conserved cysteine residues in the amino-terminal part of the protein. Chemokines are involved in inflammatory-cell recruitment and act through G-protein-coupled receptors.

RIBOZYMES

RNA molecules that function like enzymes and exert a catalytic activity. Ribozymes can be designed to cleave specific mRNAs and thereby inhibit protein synthesis.

COCCIDIOSTAT

A drug used to treat coccidiosis, an intestinal disease that is caused by a protozoan.

ANTHRAX TOXIN

Anthrax toxin is a three-part toxin that is secreted by the bacterium Bacillus anthracis and consists of protective antigen (PA), oedema factor (EF) and lethal factor (LF). PA is cleaved by furin-like proteinases at the cell surface, and cleaved PAs form a complex with EF and LF. The complex is endocytosed, and LF and EF are translocated to the cytosol where they act cytotoxically. The requirement for proteolysis of PA has been exploited by replacing the furin-like cleavage site with a sequence recognized by MMPs, in a recombinant anthrax toxin derivative.

ADAMTS

(A disintegrin and metalloproteinase with thrombospondin type 1 motifs). A family of soluble proteinases, closely related to the ADAMs, that contains domains with high homology to thrombospondin.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrc745

Further reading